ONDINE BIOMED COM SHS NPV (CDI) overview

Vancouver, Canada, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare system tens of billions of dollars a year. [1] Ondine Biomedical Inc. (LON: OBI), has treated the first patients in its nasal photodisinfection exploratory Phase 2 trial . The study will evaluate how effectively the treatment eradicates pathogens - Staphylococcus aureus - in the nose, and the occurrence of surgical site infections...